9 results about "HBx" patented technology

The invention provides a polypeptide for activating cellular immunity in chronic hepatitis B and application of the polypeptide, and belongs to the technical field of biological medicine. A polypeptide library is designed and synthesized on the basis of a preS1 structural domain for coding HBV large HBsAg, a full-length core protein Core, a polymerase protein fragment rich in T cell epitopes and an mRNA-PreS1CPX holoantigen sequence (as shown in SEQ ID NO.1) of full-length X protein HBX, and peptide fragments capable of activating T cell immunity are screened by utilizing ELISPOT and flow cytometry. Experimental results show that the polypeptide sequences as shown in SEQ ID NO.2-15 can promote HBV antigen specific immune response by stimulating CD8 + T lymphocytes to secrete IFN-gamma, so that immune activation treatment of hepatitis B is realized.

The invention discloses a mini-chromosome state characterization cell model for drug screening. The mini-chromosome state characterization cell model is a transfected cell obtained by co-transfecting a hepatocyte line with prcccDNA-HiBiT-HBx and a plasmid Cre; the invention also discloses an application of the compound C20H14F3N3S or the pharmaceutically acceptable salt thereof in preparation of an HBV (hepatitis B virus) inhibitor or a medicine for treating hepatitis B virus infectious diseases or symptoms. According to the invention, a novel anti-hepatitis B virus small molecule compound is screened by utilizing a constructed cell model, and experiments prove that the novel anti-hepatitis B virus small molecule compound can obviously reduce the expression levels of HBV total RNAs, HBeAg, HBV pgRNA and HBV nucleoprotein.

The invention discloses an application of a host factor HOXD1 in regulation and control of hepatitis B virus transcription. The research finds that HOXD1 interacts with HBx protein, so that the transcriptional activity of HBV is effectively inhibited; hBV replication can be promoted by knocking down HOXD1 expression, HBV transcription is remarkably inhibited by overexpressing HOXD1, and it is proved that the HOXD1 has a negative regulation function on virus replication; hOXD1 can be used as a potential anti-HBV drug target and is used for developing new drugs and new strategies for treating hepatitis B.

This invention relates to an immunoRaman multicolor imaging kit for the prediction and assessment of liver cancer. The immunoRaman multicolor imaging reagent contains five Raman probes, which are composed of Raman spheres and antibodies attached to the surface of the Raman spheres. The Raman spheres are polymerized from triple-bonded monomers with (i) acrylic acid or (ii) styrene and acrylic acid, with a particle size of 10–100 nm and a Raman shift of 1800–2800 cm⁻¹. ‑1 The antibodies used for the five Raman probes are selected from one of the following: AFP antibody, HBX antibody, GPC3 antibody, GS antibody, and CD34 antibody. The immunoRaman multicolor imaging reagent and kit provided by this invention can achieve one-step labeling and multiplex color development of five liver cancer-related protein markers in the same liver tissue section. Compared with multiplex fluorescence immunohistochemistry, this invention has significant advantages in both efficiency and accuracy. Experiments show that the detection results of this invention are consistent with clinical diagnostic results, demonstrating great application potential.

The invention provides siRNA for targeted degradation of hepatitis B viruses HBsAg and HBX mRNA, and relates to the technical field of biological medicines. A positive-sense strand of the siRNA comprises a base sequence as shown in SEQ ID NO. 1, and an antisense strand of the siRNA comprises a base sequence as shown in SEQ ID NO. 2; or, the positive-sense strand comprises the base sequence as shown in SEQ ID NO. 3, and the antisense strand comprises the base sequence as shown in SEQ ID NO. 4. The siRNA and the siRNA conjugate provided by the invention can significantly inhibit expression of HBsAg and HBX by targeting HBV, which indicates that the siRNA and the siRNA conjugate can be used as effective components for preparing anti-HBV drugs and for treating hepatitis B caused by HBV.

The invention discloses application of herba lycopi flavone in preparation of a medicine for treating HBV-HCC (Hepatitis B Virus-Hepatitis C Chromatography), and belongs to the technical field of biological medicines. In-vivo experiments prove that CP can effectively inhibit proliferation and metastasis of HBV-HCC (Hepatitis B Virus-Hepatitis C Chromatography) cells. In combination with in-vitro cell activity, it is proved that eupatorium flavone is the most bioactive component for inhibiting HBV-HCC cell growth, proliferation and metastasis in CP. By inhibiting the HIF-1alpha and the downstream effect of the HIF-1alpha on VEGFA signal transduction, angiogenesis induced by tumors is hindered, the growth of the tumors is limited, and the invasiveness of cancer cells is reduced, so that the possibility of metastasis is reduced. It is verified that the herba lycopi flavone can inhibit invasion and metastasis of HBV-HCC through an HBx / HIF-1alpha / VEGFA signal axis; growth and proliferation and cell metastasis of HBV-HCC cells are inhibited through an HIF-1alpha / VEGFA signal channel, so that a scientific basis is provided for anti-tumor of the herba lycopi flavone.

The present invention relates to an oligomer conjugate for use in the treatment of a viral disorder. The oligomer conjugate comprises: a) an oligomer capable of modulating a target sequence in HBx and / or HBsAg of Hepatitis B Virus (HBV) to treat said viral disorder; and b) a carrier component capable of delivering the oligomer to the liver which is linked, preferably conjugated, to the oligomer.

According to the construction method of the liver cancer mouse model, the liver cancer mouse model is obtained by conditionally knocking out an SMC6 gene from liver cells. Furthermore, the model mouse is realized by the following steps: hybridizing an SMC6flox / flox transgenic mouse and an Alb-cre transgenic mouse to obtain an F1-generation mouse, selfing the F1-generation mouse, and identifying to obtain a mouse of which the genotype is SMC6flox / flox: Alb-cre +. The invention further provides application of the liver cancer mouse model. The SMC6 gene in mouse hepatocytes is specifically knocked out to obtain a rapid primary liver cancer mouse model with the success rate of 100%, the model simulates the SMC6 degradation process of HBx, the pathological state of liver cancer caused by HBV infection is stably and truly reflected, and the model can be used for screening candidate drugs for liver cancer.

The invention relates to a new application of a homologous box gene, in particular to an application of a BARX homologous frame 1 (BARX1) and an NK1 homologous frame 1 (NKX1-1) in resisting hepatitis B virus (HBV). The invention discovers that BARX1 and NKX1-1 are novel host limiting factors of HBV for the first time. BARX1 and NKX1-1 synergistically inhibit HBV through dual mechanisms: on one hand, the degradation of HBx protein is horizontally promoted after transcription; on the other hand, the activity of an HBV enhancer II / core promoter is inhibited, so that the hepatitis B virus is inhibited. In-vivo and in-vitro experiments prove that HBV gene expression and genome replication can be remarkably reduced by overexpressing BARX1 or NKX1-1. The invention provides an effective molecular target for developing a novel anti-HBV drug and a gene therapy strategy.